Showing results (21-30 of 55) with videos related to
Sort By:
Pageof 6
Leukemia & Lymphoma|October 19, 2017
Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and GermanyErin A Zagadailov, Shelby Corman, Viktor Chirikov, et al.International Journal of Radiation Oncology, Biology, Physics|April 15, 2014
Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology GroupTim Illidge, Lena Specht, Joachim Yahalom, et al.Blood|April 11, 2020
ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemicJoachim Yahalom, Bouthaina Shbib Dabaja, Umberto Ricardi, et al.British Journal of Haematology|September 22, 2018
Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United KingdomPaul J Bröckelmann, Suzanne McMullen, J Ben Wilson, et al.European Journal of Cancer (Oxford, England : 1990)|January 16, 2008
Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshopPier Luigi Zinzani, Francesco d'Amore, Emilio Bombardieri, et al.International Journal of Radiation Oncology, Biology, Physics|June 25, 2013
Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG)Lena Specht, Joachim Yahalom, Tim Illidge, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2021
Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin LymphomaDavid J Cutter, Johanna Ramroth, Patricia Diez, et al.Blood Advances|January 8, 2025
Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international studyElizabeth H Phillips, Nicholas Counsell, Tim Illidge, et al.The Lancet. Oncology|February 4, 2021
4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trialPeter Hoskin, Biliana Popova, Oliver Schofield, et al.Blood|March 28, 2007
Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantationFranck Morschhauser, Tim Illidge, Damien Huglo, et al.Pageof 6